Form 4: Astera Labs Exec Sells Shares Via 10b5-1 Plan

Astera Labs President and COO Sanjay Gajendra reported the sale of over 600,000 shares of common stock, executed through a pre-arranged Rule 10b5-1 trading plan.

Summary

• Sanjay Gajendra, President and COO of Astera Labs, reported transactions involving the sale and transfer of company common stock.
• On May 21, 2026, Gajendra sold a total of 1,067,190 shares of common stock through a Rule 10b5-1 trading plan at weighted average prices ranging from $289.1303 to $293.0293.
• These sales were conducted in multiple transactions at prices within specified ranges, with details to be provided upon request.
• On May 22, 2026, Gajendra transferred 226,189 shares of common stock to an estate planning trust (Trust 1) for no consideration.
• Following these transactions, Gajendra directly beneficially owns 1,209,668 shares and indirectly beneficially owns 5,290,402 shares through Trust 1.
• Additionally, Gajendra disclaims beneficial ownership of 615,000 shares held by Trust 2 and 615,000 shares held by Trust 3, except to the extent of his pecuniary interest.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to the significant volume of shares sold by a top executive, despite the use of a Rule 10b5-1 plan.

Negatives

• Significant sale of company stock by a key executive, totaling over 1 million shares across multiple transactions.
• The sales occurred at prices up to $293.03 per share, indicating a substantial value of shares being divested.

Risks

• The sale of a large number of shares by a high-ranking executive could be interpreted negatively by the market, potentially impacting investor sentiment.
• While executed under a Rule 10b5-1 plan, the sheer volume of shares sold might raise questions about the executive's confidence in the company's future stock performance.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Management Comments

• The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2025.
• The Reporting Person disclaims beneficial ownership of these securities [held by Trust 2 and Trust 3], except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Industry Context

StockSavvy.ai notes that insider selling, even under a Rule 10b5-1 plan, can be a sensitive indicator for investors in the semiconductor and data infrastructure sectors, where Astera Labs operates. Such sales can sometimes precede periods of increased volatility or signal a lack of immediate upside conviction from management.

Related Party Transactions

• Transfer of 226,189 shares of Issuer Common Stock to an estate planning trust (Trust 1) for no consideration on May 22, 2026.
• The reporting person is a trustee of Trust 1, which holds 5,290,402 shares indirectly.
• The reporting person disclaims beneficial ownership of shares held by Trust 2 (615,000 shares) and Trust 3 (615,000 shares).

Stakeholder Impact

• Shareholders may view the large sale by a key executive with concern, potentially leading to short-term negative pressure on the stock price.
• Employees holding stock options or grants might be influenced by the executive's selling activity, impacting morale or their own investment decisions.

Key Dates

Recommendation

While the sale of over a million shares by a key executive is a negative signal, it was executed under a pre-established Rule 10b5-1 plan, which mitigates concerns about opportunistic trading. The filing itself does not provide financial performance data or future guidance to warrant a sell or strong sell recommendation. Therefore, a 'hold' recommendation is appropriate, advising investors to monitor further developments and company performance.

Keywords

Astera Labs, ALAB, Form 4, Insider Trading, Stock Sale, Rule 10b5-1, Sanjay Gajendra, Beneficial Ownership, Common Stock, Executive Transactions